Omada Health (NASDAQ:OMDA) CEO Sells $259,705.60 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 14,960 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $17.36, for a total value of $259,705.60. Following the completion of the transaction, the chief executive officer owned 411,861 shares of the company’s stock, valued at $7,149,906.96. The trade was a 3.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Omada Health Price Performance

Shares of OMDA stock opened at $17.64 on Friday. Omada Health, Inc. has a one year low of $10.28 and a one year high of $26.92. The stock has a fifty day moving average price of $15.84 and a 200 day moving average price of $14.80. The stock has a market cap of $1.05 billion and a P/E ratio of -65.33.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The firm had revenue of $78.05 million for the quarter. Equities research analysts anticipate that Omada Health, Inc. will post -0.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Omada Health from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Citigroup reaffirmed an “outperform” rating on shares of Omada Health in a report on Friday, May 8th. Morgan Stanley lowered their price objective on Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, March 6th. The Goldman Sachs Group reissued a “buy” rating on shares of Omada Health in a report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Omada Health in a research note on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.91.

Hedge Funds Weigh In On Omada Health

Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Omada Health in the fourth quarter valued at about $29,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Omada Health during the fourth quarter worth approximately $32,000. Raymond James Financial Inc. bought a new position in shares of Omada Health in the second quarter valued at approximately $32,000. Inlight Wealth Management LLC bought a new position in shares of Omada Health in the fourth quarter valued at approximately $45,000. Finally, Strs Ohio boosted its holdings in shares of Omada Health by 151.0% in the 4th quarter. Strs Ohio now owns 4,267 shares of the company’s stock worth $67,000 after acquiring an additional 2,567 shares in the last quarter.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.